Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, multilayer - excipient ingredients: magnesium stearate; meglumine; sorbitol; sodium hydroxide; microcrystalline cellulose; povidone; colloidal anhydrous silica; maize starch; pregelatinised maize starch; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - telmisartan, quantity: 40 mg; amlodipine besilate, quantity: 13.87 mg (equivalent: amlodipine, qty 10 mg) - tablet, multilayer - excipient ingredients: colloidal anhydrous silica; sodium hydroxide; sorbitol; magnesium stearate; pregelatinised maize starch; povidone; microcrystalline cellulose; maize starch; meglumine; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

boehringer ingelheim pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg); telmisartan, quantity: 80 mg - tablet, multilayer - excipient ingredients: pregelatinised maize starch; microcrystalline cellulose; meglumine; magnesium stearate; maize starch; colloidal anhydrous silica; sodium hydroxide; povidone; sorbitol; colour - treatment of hypertension. treatment should not be initiated with this fixed-dose combination. (see dosage and administration)

Írland - enska - HPRA (Health Products Regulatory Authority)

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/5 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Írland - enska - HPRA (Health Products Regulatory Authority)

accord healthcare limited - amlodipine (as amlodipine besilate ph. eur.); olmesartan medoxomil - film-coated tablet - 40/10 mg/mg - angiotensin ii antagonists and calcium channel blockers; olmesartan medoxomil and amlodipine

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 40 mg - tablet - excipient ingredients: sodium hydroxide; mannitol; sodium stearylfumarate; meglumine; magnesium stearate; povidone - apo-telmisartan is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 80 mg - tablet - excipient ingredients: sodium stearylfumarate; magnesium stearate; mannitol; meglumine; sodium hydroxide; povidone - apo-telmisartan is indicated for:,treatment of hypertension,prevention of cardiovascular morbidity and mortality in patients 55 years or older with coronary artery disease, peripheral artery disease, previous stroke, transient ischaemic attack or high risk diabetes with evidence of end organ damage (see clinical trials)

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 80 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, multilayer - excipient ingredients: lactose monohydrate; magnesium stearate; povidone; sodium hydroxide; mannitol; meglumine; sodium stearylfumarate; purified water; iron oxide red - apo telmisartan hctz is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Ástralía - enska - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - telmisartan, quantity: 40 mg; hydrochlorothiazide, quantity: 12.5 mg - tablet, multilayer - excipient ingredients: sodium hydroxide; mannitol; povidone; lactose monohydrate; meglumine; magnesium stearate; sodium stearylfumarate; purified water; iron oxide red - apo telmisartan hctz is indicated for the treatment of hypertension. treatment should not be initiated with these combinations.

Bandaríkin - enska - NLM (National Library of Medicine)

proficient rx lp - amlodipine besylate (unii: 864v2q084h) (amlodipine - unii:1j444qc288), benazepril hydrochloride (unii: n1sn99t69t) (benazeprilat - unii:jrm708l703) - amlodipine 10 mg - amlodipine besylate and benazepril hydrochloride capsules, usp are indicated for the treatment of hypertension in patients not adequately controlled on monotherapy with either agent.  pregnancy category d use of drugs that act on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death.  resulting oligohydramnios can be associated with fetal lung hypoplasia and skeletal deformations.  potential neonatal adverse effects include skull hypoplasia, anuria, hypotension, renal failure, and death.  when pregnancy is detected, discontinue amlodipine besylate and benazepril hydrochloride as soon as possible.  these adverse outcomes are usually associated with use of these drugs in the second and third trimester of pregnancy.  most epidemiologic studies examining fetal abnormalities after exposure to antihypertensive use in the first trimester have not distinguished drugs affecting the renin-angiotensin system fro